Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 11/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6144506 | 1.00 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL6806111 | 0.94 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL6806105 | 0.94 | KCNH2 (0.58) | KCNH2 | |
| SCHEMBL6143165 | 0.93 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL6143161 | 0.93 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL6145237 | 0.92 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL6145234 | 0.92 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL6145122 | 0.90 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL6145126 | 0.90 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL6142960 | 0.89 | KCNH2 (0.53) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6841562-B2 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | AVENTIS PHARMA S.A. (FR) | 2005-01-11 | — | — | US | disclosed |
| US-20040082610-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | NOVEXEL (FR) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082610-A1 | Quinolylpropylpiperidine derivatives, intermediates and compositions containing them, and preparation therefor | RRS1, MRPL21, FARSB | KCNH2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.